About: Anti-Diarrheal Effects of Diosmectite in the Treatment of Acute Diarrhea in Children: A Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-Diarrheal Effects of Diosmectite in the Treatment of Acute Diarrhea in Children: A Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anti-Diarrheal Effects of Diosmectite in the Treatment of Acute Diarrhea in Children: A Review
Creator	Dupont, Christophe Vernisse, Bernard
Source	Medline; PMC
abstract	Acute diarrhea caused by an infectious organism is highly prevalent, particularly in developing countries, and is usually self-limiting. The condition is a major contributor to the global disease burden and is associated with a significant economic cost. The disease is common in children aged <5 years. It occurs as the result of exposure to a diarrheogenic agent that alters intestinal absorption and/or secretion, resulting in an increase in the volume of water that enters the colon beyond that which can be absorbed. Diarrhea almost always occurs by one or more of four mechanisms: disruption of osmotic forces in the intestine; disruption of normal secretory processes; disruption of epithelial cells or the epithelial tight junctions; or motility disorders. Oral rehydration therapy (ORT) is central to the management of acute diarrhea, and is sufficient to prevent complications due to dehydration in most patients while the disease runs its course. However, ORT has no effect on the duration of the disease or frequency of bowel motions, and any agent that could meet these needs would therefore be a useful addition to ORT. Diosmectite is a natural aluminomagnesium silicate clay with a lamellar, non-fibrous crystalline structure that gives it strong adsorbent properties. Its mechanisms of action are not yet fully understood, but are probably multiple. Diosmectite reduces inflammation, modifies mucus rheologic properties, inhibits mucolysis, and adsorbs bacteria, bacterial enterotoxins, viruses and other potentially diarrheogenic substances. A number of studies have shown that diosmectite reduces the duration of diarrhea and decreases the frequency of bowel motions after 2 days of treatment in children with mild-to-moderate acute diarrhea. Two recent trials have indicated a reduction in stool output with diosmectite. Because of its very favorable safety profile, with no serious adverse effects, diosmectite is frequently used, mainly in European countries but also in Asia and Africa. Diosmectite should be used as an adjunct, not an alternative, to ORT and, when needed, to antibacterial therapy.
has issue date	2012-08-22(xsd:dateTime)
bibo:doi	10.2165/00148581-200911020-00001
bibo:pmid	19301931
has license	no-cc
sha1sum (hex)	3b3004c9a1c9e47851902124d45081862b27f3b9
schema:url	https://doi.org/10.2165/00148581-200911020-00001
resource representing a document's title	Anti-Diarrheal Effects of Diosmectite in the Treatment of Acute Diarrhea in Children: A Review
has PubMed Central identifier	PMC7100234
has PubMed identifier	19301931
schema:publication	Paediatr Drugs
resource representing a document's body	covid:3b3004c9a1c9e47851902124d45081862b27f3b9#body_text
is schema:about of	named entity 'Acute' named entity 'ACUTE DIARRHEA' named entity 'ANTI-DIARRHEAL' named entity 'CHILDREN' named entity 'DIOSMECTITE' named entity 'REVIEW' named entity 'EFFECTS' named entity 'TREATMENT' named entity 'developed countries' named entity 'diarrhea' named entity 'mucus' named entity 'TNFa' named entity 'lumen' named entity 'cholera toxin' named entity 'HT29' named entity 'Diosmectite' named entity 'reduces inflammation' named entity 'adsorption' named entity 'pathogenic organisms' named entity 'cGMP' named entity 'WHO' named entity 'Diosmectite' named entity 'diosmectite' named entity 'epithelial cells' named entity 'Anti-Diarrheal' named entity 'Diosmectite' named entity 'diosmectite' named entity 'antisecretory' named entity 'natural defense' named entity 'luminal' named entity 'mucin 2' named entity 'Diarrhea' named entity 'ileal' named entity 'inflammatory response' named entity 'rotavirus' named entity 'secretory diarrhea' named entity 'rotavirus' named entity 'outpatient' named entity 'organism' named entity 'diosmectite' named entity 'diosmectite' named entity 'intestinal epithelial cells' named entity 'diosmectite' named entity 'diosmectite' named entity 'diosmectite' named entity 'diosmectite' named entity 'placebo' named entity 'infectious diarrhea' named entity 'placebo' named entity 'pathogenic bacteria' named entity 'epithelial layer' named entity 'nuclear material' named entity 'enterocyte' named entity 'gene' named entity 'controlled studies' named entity 'adsorb' named entity 'incubation' named entity 'smectite' named entity 'diarrhea' named entity 'mucosa' named entity 'diarrhea' named entity 'lamellar structure' named entity 'ORS' named entity '95% CI' named entity 'inflammatory response' named entity 'ORS' named entity 'cAMP' named entity 'bacteria' named entity 'mechanisms of action' named entity 'outpatient' named entity 'mucin' named entity 'Diarrhea' named entity 'developed countries' named entity 'epithelial cells' named entity 'diosmectite' named entity 'Adhesion' named entity 'diosmectite' named entity 'Diosmectite' named entity 'ORT' named entity 'antigens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software